Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacquelyn W Chou

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of Managed Care & Specialty Pharmacy|October 15, 2021
Schizophrenia population health management: perspectives of and lessons learned from population health decision makersMeaghan Roach, Dee Lin, Marlon Graf, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Cost-effectiveness of genome sequencing for diagnosing patients with undiagnosed rare genetic diseasesDevin Incerti, Xiang-Ming Xu, Jacquelyn W Chou, et al.
Journal of Market Access & Health Policy|November 26, 2024
Economic Evidence on Cost Sharing and Alternative Insurance Designs to Address Moral and Behavioral Hazards in High-Income Health Care Systems: A Systematic ReviewMarlon Graf, James R Baumgardner, Ulrich Neumann, et al.
Headache|March 15, 2023
Expert consensus established around flexible, individualized migraine treatment utilizing a modified Delphi panelMarlon Graf, Edward Kim, Iris Brewer, et al.
JAMA Oncology|July 17, 2015
Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung CancerDarius N Lakdawalla, Jacquelyn W Chou, Mark T Linthicum, et al.
The American Journal of Managed Care|June 30, 2016
Value of improved lipid control in patients at high risk for adverse cardiac eventsAnupam B Jena, Daniel M Blumenthal, Warren Stevens, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|July 7, 2025
Delphi panel to understand the real-world occurrence and management of ofatumumab injection-related reactions among healthcare providers of people with relapsing multiple sclerosisShiv Saidha, John Kramer, Brandon Brown, et al.
International Journal of Clinical Practice|March 20, 2024
The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic DiseasesMeaghan Roach, Natalie Land, Jennifer Hernandez, et al.
JAMA Psychiatry|January 28, 2026
National and State Societal Costs of Schizophrenia in the US in 2024Holly B Krasa, James R Baumgardner, Iris P Brewer, et al.
Psychiatric Services (Washington, D.C.)|July 16, 2016
Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral AntipsychoticsJoanna P MacEwan, Siddhesh A Kamat, Ruth A Duffy, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Managed Care & Specialty Pharmacy|October 15, 2021
Schizophrenia population health management: perspectives of and lessons learned from population health decision makersMeaghan Roach, Dee Lin, Marlon Graf, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Cost-effectiveness of genome sequencing for diagnosing patients with undiagnosed rare genetic diseasesDevin Incerti, Xiang-Ming Xu, Jacquelyn W Chou, et al.
Journal of Market Access & Health Policy|November 26, 2024
Economic Evidence on Cost Sharing and Alternative Insurance Designs to Address Moral and Behavioral Hazards in High-Income Health Care Systems: A Systematic ReviewMarlon Graf, James R Baumgardner, Ulrich Neumann, et al.
Headache|March 15, 2023
Expert consensus established around flexible, individualized migraine treatment utilizing a modified Delphi panelMarlon Graf, Edward Kim, Iris Brewer, et al.
JAMA Oncology|July 17, 2015
Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung CancerDarius N Lakdawalla, Jacquelyn W Chou, Mark T Linthicum, et al.
The American Journal of Managed Care|June 30, 2016
Value of improved lipid control in patients at high risk for adverse cardiac eventsAnupam B Jena, Daniel M Blumenthal, Warren Stevens, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|July 7, 2025
Delphi panel to understand the real-world occurrence and management of ofatumumab injection-related reactions among healthcare providers of people with relapsing multiple sclerosisShiv Saidha, John Kramer, Brandon Brown, et al.
International Journal of Clinical Practice|March 20, 2024
The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic DiseasesMeaghan Roach, Natalie Land, Jennifer Hernandez, et al.
JAMA Psychiatry|January 28, 2026
National and State Societal Costs of Schizophrenia in the US in 2024Holly B Krasa, James R Baumgardner, Iris P Brewer, et al.
Psychiatric Services (Washington, D.C.)|July 16, 2016
Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral AntipsychoticsJoanna P MacEwan, Siddhesh A Kamat, Ruth A Duffy, et al.
Pageof 3